Teva Pharmaceutical Industries News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

23.12.24	Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
20.12.24	Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025 (GlobeNewswire)
17.12.24	Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease (GlobeNewswire)
11.12.24	Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients (GlobeNewswire)
06.12.24	Teva Pharma To Divest Teva-Takeda Business Venture In Japan To JKI (RTTNews)
06.12.24	Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan (GlobeNewswire)
04.12.24	Teva präsentiert positive Wirksamkeits- und Sicherheitsdaten von AJOVY® (Fremanezumab) zur Vorbeugung episodischer Migräne bei Kindern und Jugendlichen aus der Phase-III-Studie SPACE (GlobeNewswire)
04.12.24	Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial (GlobeNewswire)
26.11.24	Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
08.11.24	Teva to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
06.11.24	Teva Pharma Q3 Beats Market, Lifts FY24 Outlook; Stock Up (RTTNews)
02.11.24	Teva Presents New Research On Schizophrenia, Highlighting SOLARIS Trial Results For TEV-749 (RTTNews)
02.11.24	Teva Presents IMPACT-TD Data On Tardive Dyskinesia, Revealing Patient Experience Variations (RTTNews)
01.11.24	Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition (GlobeNewswire)
01.11.24	Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanza (GlobeNewswire)
31.10.24	Teva Statement on European Commission Decision; Company to Appeal (GlobeNewswire)
22.10.24	Alvotech And Teva Pharmaceuticals Announce Expansion Of SELARSDI's Indications (RTTNews)
22.10.24	Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (us (GlobeNewswire)
17.10.24	Amicus Therapeutics Settles Galafold Patent Litigation With Teva (RTTNews)
11.10.24	Teva Pharma To Pay $450 Mln To Settle Kickback Allegations (RTTNews)
08.10.24	Teva Pharma: FDA To Review BLA For TVB-009P - Quick Facts (RTTNews)
08.10.24	Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA (GlobeNewswire)
03.10.24	Teva, MAbxience Enter Licensing Deal For Development Of Anti PD-1 Oncology Biosimilar Candidate (RTTNews)
03.10.24	Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate (GlobeNewswire)
01.10.24	Teva Pharma Launches Octreotide Acetate For Injectable Suspension - Quick Facts (RTTNews)
01.10.24	Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S. (GlobeNewswire)
30.09.24	Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024 (GlobeNewswire)
23.09.24	Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia (GlobeNewswire)
21.09.24	Teva : New Data Offer Insights On Switching Schizophrenia Patients To UZEDY From Perseris (RTTNews)
21.09.24	Teva Reports Positive Phase 3 Results For TEV-749 In Schizophrenia Treatment (RTTNews)
21.09.24	Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed (GlobeNewswire)
21.09.24	New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000) (GlobeNewswire)
11.09.24	Teva to Present at the Bank of America 2024 Global Healthcare Conference (GlobeNewswire)
26.08.24	Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
31.07.24	Teva Pharma Q2 Results Beat View, Raises Annual Outlook Above Estimates, Stock Rises (RTTNews)
25.06.24	Teva To Settle Litigation With Israel Tax Authority (RTTNews)
24.06.24	Teva Launches Authorized Generic Of Victoza For Type 2 Diabetes Patients In US (RTTNews)
30.05.24	Teva's AUSTEDO XR Receives FDA Approval For Once-Daily Therapy At Therapeutic Doses (RTTNews)
21.05.24	Teva Says Simlandi Injection Now Available In U.S. (RTTNews)
08.05.24	Teva And Medincell Say Phase 3 SOLARIS Study In Schizophrenia Met Primary Goal (RTTNews)
08.05.24	Teva Pharmaceutical Industries Posts Narrower Loss In Q1 - Update (RTTNews)
08.05.24	Teva Pharmaceutical Industries Limited Q1 Earnings Summary (RTTNews)
30.04.24	Alvotech To Manufacture Its High-concentration Interchangeable Biosimilar To Humira For Quallent (RTTNews)
23.04.24	Supreme Court Denies Vanda Pharma' Petition In HETLIOZ Litigation Against Teva, Apotex (RTTNews)
16.04.24	Teva Confirms Austedo's Effectiveness For HD Chorea With The 4-week Titration Kit (RTTNews)
11.04.24	Teva Confirms Efficacy, Safety Of AJOVY In Prevention Of Migraine - Quick Facts (RTTNews)
04.04.24	Teva Announces Strategic Alliance With MAbxience For Oncology Biosimilar Candidate (RTTNews)
03.04.24	UroGen Pharma Files Patent Infringement Lawsuit Against Teva Pharma (RTTNews)
24.02.24	Alvotech And Teva Announce U.S. Approval Of SIMLANDI Injection (RTTNews)
20.02.24	Teva Pharmaceuticals Announces Positive Data For Anti-TL1A Asset (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

29.12.24		Novartis-Aktie: Novartis muss sich erneut Schmiergeld-Vorwürfen stellen
27.12.24		Anleger in New York halten sich zurück: Dow Jones beendet die Freitagssitzung im Minus
27.12.24		BioNTech und Pfizer zahlen Milliardenbetrag für Impfstoffvergleich in USA - BioNTech-Aktie fester
27.12.24		Optimismus in Zürich: SMI zum Ende des Freitagshandels mit grünem Vorzeichen
27.12.24		SLI-Handel aktuell: Zum Handelsende Gewinne im SLI
27.12.24		Börse London in Grün: FTSE 100 zum Ende des Freitagshandels freundlich
27.12.24		Verluste in New York: Dow Jones präsentiert sich zum Start leichter
27.12.24		Börse London: FTSE 100 auf grünem Terrain

29.12.24

Novartis-Aktie: Novartis muss sich erneut Schmiergeld-Vorwürfen stellen

27.12.24

Anleger in New York halten sich zurück: Dow Jones beendet die Freitagssitzung im Minus

27.12.24

BioNTech und Pfizer zahlen Milliardenbetrag für Impfstoffvergleich in USA - BioNTech-Aktie fester

27.12.24

Optimismus in Zürich: SMI zum Ende des Freitagshandels mit grünem Vorzeichen

27.12.24

SLI-Handel aktuell: Zum Handelsende Gewinne im SLI

27.12.24

Börse London in Grün: FTSE 100 zum Ende des Freitagshandels freundlich

27.12.24

Verluste in New York: Dow Jones präsentiert sich zum Start leichter

27.12.24

Börse London: FTSE 100 auf grünem Terrain

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Teva Pharmaceutical Industries Ltd. (spons. ADRs)

Aktien Top/Flop

Teva Pharmaceutical Industries Peer Group Nachrichten

Meistgelesene Nachrichten